These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 34715057)

  • 61. SARS-CoV-2-associated multisystem inflammatory syndrome in children: clinical manifestations and the role of infliximab treatment.
    Abdel-Haq N; Asmar BI; Deza Leon MP; McGrath EJ; Arora HS; Cashen K; Tilford B; Charaf Eddine A; Sethuraman U; Ang JY
    Eur J Pediatr; 2021 May; 180(5):1581-1591. PubMed ID: 33452570
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Treatment of Kawasaki disease with a moderate dose (1 g/kg) of intravenous immunoglobulin.
    Khowsathit P; Hong-Hgam C; Khositseth A; Wanitkun S
    J Med Assoc Thai; 2002 Nov; 85 Suppl 4():S1121-6. PubMed ID: 12549785
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Methylprednisolone Pulse Therapy or Additional IVIG for Patients with IVIG-Resistant Kawasaki Disease.
    Wang Z; Chen F; Wang Y; Li W; Xie X; Liu P; Zhang X; Zhang L; Huang P
    J Immunol Res; 2020; 2020():4175821. PubMed ID: 33299898
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Corticosteroids in the initial treatment of Kawasaki disease: report of a randomized trial.
    Sundel RP; Baker AL; Fulton DR; Newburger JW
    J Pediatr; 2003 Jun; 142(6):611-6. PubMed ID: 12838187
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Efficacy of intravenous immune globulin therapy combined with dexamethasone for the initial treatment of acute Kawasaki disease.
    Jibiki T; Terai M; Kurosaki T; Nakajima H; Suzuki K; Inomata H; Terashima I; Honda T; Yasukawa K; Hamada H; Kohno Y
    Eur J Pediatr; 2004 Apr; 163(4-5):229-33. PubMed ID: 14963702
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical symptoms of patients with Kawasaki disease include smoldering fever.
    Iwasa M; Inukai S
    Pediatr Int; 2023; 65(1):e15541. PubMed ID: 36975765
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS; Raskin A; Gudausky TM; Kirkpatrick E
    Am J Ther; 2016; 23(6):e1293-e1299. PubMed ID: 25611359
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Variability in Response to Intravenous Immunoglobulin in the Treatment of Kawasaki Disease.
    Downie ML; Manlhiot C; Latino GA; Collins TH; Chahal N; Yeung RS; McCrindle BW
    J Pediatr; 2016 Dec; 179():124-130.e1. PubMed ID: 27659027
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effect of i.v. immunoglobulin in the first 4 days of illness in Kawasaki disease.
    Shiozawa Y; Inuzuka R; Shindo T; Mafune R; Hayashi T; Hirata Y; Shimizu N; Inatomi J; Yokoyama Y; Namai Y; Oda Y; Takamizawa M; Harita Y; Kawahara T; Oka A
    Pediatr Int; 2018 Apr; 60(4):334-341. PubMed ID: 29292568
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Kawasaki disease: a comprehensive review of treatment options.
    Patel RM; Shulman ST
    J Clin Pharm Ther; 2015 Dec; 40(6):620-5. PubMed ID: 26547265
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Withdrawal of infliximab or concomitant immunosuppressant therapy in patients with Crohn's disease on combination therapy (SPARE): a multicentre, open-label, randomised controlled trial.
    Louis E; Resche-Rigon M; Laharie D; Satsangi J; Ding N; Siegmund B; D'Haens G; Picon L; Bossuyt P; Vuitton L; Irving P; Viennot S; Lamb CA; Pollok R; Baert F; Nachury M; Fumery M; Gilletta C; Almer S; Ben-Horin S; Bouhnik Y; Colombel JF; Hertervig E;
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):215-227. PubMed ID: 36640794
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The effects of glucocorticoid plus intravenous immunoglobulin (IVIG) vs IVIG alone on platelet activation in children with Kawasaki disease.
    Wang QQ; Zheng LY; Zhao S
    Turk J Pediatr; 2023; 65(4):640-649. PubMed ID: 37661679
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Intravenous immunoglobulin preparation type: association with outcomes for patients with acute Kawasaki disease.
    Manlhiot C; Yeung RS; Chahal N; McCrindle BW
    Pediatr Allergy Immunol; 2010 May; 21(3):515-21. PubMed ID: 20546528
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Primary adjunctive corticosteroid therapy is associated with improved outcomes for patients with Kawasaki disease with coronary artery aneurysms at diagnosis.
    Friedman KG; Gauvreau K; Baker A; Son MB; Sundel R; Dionne A; Giorgio T; De Ferranti S; Newburger JW
    Arch Dis Child; 2021 Mar; 106(3):247-252. PubMed ID: 32943389
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Infliximab treatment for refractory Kawasaki syndrome.
    Burns JC; Mason WH; Hauger SB; Janai H; Bastian JF; Wohrley JD; Balfour I; Shen CA; Michel ED; Shulman ST; Melish ME
    J Pediatr; 2005 May; 146(5):662-7. PubMed ID: 15870671
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Association between duration of fever before treatment and intravenous immunoglobulin resistance in Kawasaki disease].
    Wang X; Pan SL; DU ZH; Ji ZX; Luo G; Sun HX; Ma SJ
    Zhongguo Dang Dai Er Ke Za Zhi; 2022 Apr; 24(4):399-404. PubMed ID: 35527415
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A case of intravenous immunoglobulin-resistant Kawasaki disease treated with methotrexate.
    Lee MS; An SY; Jang GC; Kim DS
    Yonsei Med J; 2002 Aug; 43(4):527-32. PubMed ID: 12205742
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Delayed intravenous immunoglobulin treatment increased the risk of coronary artery lesions in children with Kawasaki disease at different status.
    Qiu H; He Y; Rong X; Ren Y; Pan L; Chu M; Wu R; Shi H
    Postgrad Med; 2018 May; 130(4):442-447. PubMed ID: 29745742
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Intravenous immunoglobulin for the treatment of Kawasaki disease in children.
    Oates-Whitehead RM; Baumer JH; Haines L; Love S; Maconochie IK; Gupta A; Roman K; Dua JS; Flynn I
    Cochrane Database Syst Rev; 2003; 2003(4):CD004000. PubMed ID: 14584002
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea.
    Hur G; Song MS; Sohn S; Lee HD; Kim GB; Cho HJ; Yoon KL; Joo CU; Hyun MC; Kim CH
    Korean Circ J; 2019 Feb; 49(2):183-191. PubMed ID: 30468032
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.